Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELUW) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Celularity (CELUW) over the last 6 years, with Q3 2025 value amounting to $120000.0.

  • Celularity's Cash & Equivalents fell 977.44% to $120000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $120000.0, marking a year-over-year decrease of 977.44%. This contributed to the annual value of $738000.0 for FY2024, which is 22511.01% up from last year.
  • Per Celularity's latest filing, its Cash & Equivalents stood at $120000.0 for Q3 2025, which was down 977.44% from $863000.0 recorded in Q2 2025.
  • Over the past 5 years, Celularity's Cash & Equivalents peaked at $73.3 million during Q3 2021, and registered a low of $211.0 during Q2 2021.
  • Its 5-year average for Cash & Equivalents is $14.2 million, with a median of $863000.0 in 2025.
  • In the last 5 years, Celularity's Cash & Equivalents tumbled by 9997.06% in 2021 and then skyrocketed by 1800748293.84% in 2022.
  • Over the past 5 years, Celularity's Cash & Equivalents (Quarter) stood at $37.2 million in 2021, then tumbled by 62.5% to $14.0 million in 2022, then crashed by 98.37% to $227000.0 in 2023, then skyrocketed by 225.11% to $738000.0 in 2024, then plummeted by 83.74% to $120000.0 in 2025.
  • Its Cash & Equivalents stands at $120000.0 for Q3 2025, versus $863000.0 for Q2 2025 and $293000.0 for Q1 2025.